| Symbol | CRVO |
|---|---|
| Name | CERVOMED INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 300 EAST MAIN STREET,SUITE 201, CHARLOTTESVILLE, Virginia, 22902, United States |
| Telephone | +1 434 220-0718 |
| Fax | — |
| — | |
| Website | https://www.cervomed.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001053691 |
| Description | CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimers disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. Additional info from NASDAQ: |
New Form S-3 - CervoMed Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001437749-26-022812 <b>Size:</b> 597 KB
Read moreCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimers Association International Conference (AAIC) 2026
Read moreNew Form SCHEDULE 13G - CervoMed Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001649553-26-000070 <b>Size:</b> 15 KB
Read more(99% Neutral) CERVOMED INC. (CRVO) Announces Enrollment Update for offering Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process
Read moreCervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Read moreNew Form 424B5 - CervoMed Inc. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001437749-26-021218 <b>Size:</b> 446 KB
Read moreCervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Read moreCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
Read moreDirector BOGER JOSHUA S 🟢 acquired 2.9M shares (2 derivative) of CervoMed Inc. (CRVO) at $3.32 ($9.2M) Transaction Date: Jun 11, 2026 | Filing ID: 020691
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07033481 | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | Phase2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Active_Not_Recruiting | 2025-10-02 | 2026-10-01 | ClinicalTrials.gov |
| NCT07033481 | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | Phase2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Active_Not_Recruiting | 2025-10-02 | 2026-10-01 | ClinicalTrials.gov |
| NCT06987643 | A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recove… | Phase2 | Moderate to Severe Acute Ischaemic Stroke | Active_Not_Recruiting | 2025-06-20 | 2026-10-31 | ClinicalTrials.gov |
| NCT06987643 | A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recove… | Phase2 | Moderate to Severe Acute Ischaemic Stroke | Active_Not_Recruiting | 2025-06-20 | 2026-10-31 | ClinicalTrials.gov |
| NCT06815965 | A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | Phase2 | Dementia With Lewy Bodies (DLB) | Completed | 2024-10-16 | 2026-03-25 | ClinicalTrials.gov |
| NCT06815965 | A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | Phase2 | Dementia With Lewy Bodies (DLB) | Completed | 2024-10-16 | 2026-03-25 | ClinicalTrials.gov |
| NCT05869669 | RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy … | Phase2 | Dementia With Lewy Bodies | Completed | 2023-05-01 | 2025-06-16 | ClinicalTrials.gov |
| NCT05869669 | RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy … | Phase2 | Dementia With Lewy Bodies | Completed | 2023-05-01 | 2025-06-16 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Moderate to Severe Acute Ischaemic Stroke | ACTIVE_NOT_RECRUITING | NCT06987643 |
| Neflamapimod | Other | Phase PHASE2 | Moderate to Severe Acute Ischaemic Stroke | ACTIVE_NOT_RECRUITING | NCT06987643 |
| neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies (DLB) | COMPLETED | NCT06815965 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | ACTIVE_NOT_RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | ACTIVE_NOT_RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Acute Ischaemic Stroke | RECRUITING | NCT06987643 |
| Neflamapimod | Other | Phase PHASE2 | Moderate to Severe Acute Ischaemic Stroke | RECRUITING | NCT06987643 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies (DLB) | COMPLETED | NCT06815965 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| neflamapimod | DRUG | Phase PHASE2 | Dementia With Lewy Bodies (DLB) | COMPLETED | NCT06815965 |
| Placebo | DRUG | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | DRUG | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |